Original Source(s)
Related Content
New Label Expansion in Generalized Myasthenia Gravis
Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.
May 11, 2026
-
2 min
Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.
May 11, 2026